ANTIBODY-DRUG CONJUGATES CONTAINING AN ANTI-MESOTHELIN ANTIBODY AND USES THEREOF

The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, an N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker,...

Full description

Saved in:
Bibliographic Details
Main Authors CHUANG, Shih-Hsien, YU, Cheng-Chou, SUN, Wei-Ting, LAI, Chun-Liang, WEI, Win-Yin, HUANG, Chao-Yang, TSAI, Shih-Chong, LAILEE, Ying-Shuan, LIN, Wun-Huei
Format Patent
LanguageEnglish
French
Published 27.01.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides an immunoconjugate includes an antibody comprising an antigen-binding fragment that specifically binds to an epitope in mesothelin, an N-glycan binding domain and an N-glycan; a linker linking to the N-glycan; and a payload A and a payload B conjugated to the linker, respectively; wherein the payload A and the payload B are the same or different. A pharmaceutical composition comprises the immunoconjugate and a method for treating cancer are also provided in the disclosure. La présente divulgation concerne un immunoconjugué qui comprend un anticorps comprenant un fragment de liaison à l'antigène qui se lie spécifiquement à un épitope de la mésothéline, un domaine de liaison à N-glycane et un N-glycane; un lieur se liant au N-glycane; et une charge utile A et une charge utile B conjuguées au lieur, respectivement; la charge utile A et la charge utile B étant identiques ou différentes. La divulgation concerne également une composition pharmaceutique comprenant l'immunoconjugué et une méthode de traitement du cancer.
Bibliography:Application Number: WO2021US35972